CBD254-011.pdf

PDF 47 KB Posted

Attached to
OPEN TOPIC - Expeditionary Biologics-on-Demand (BOND)
Solicitation number
CBD254-011
Issued by

About this file

This is a federal contract opportunity solicitation for an open topic research program focused on Expeditionary Biologics-on-Demand (BOND) systems under program number CBD254-011. The solicitation seeks proposals for developing portable, high-performance protein production systems for point-of-care applications in biomedical and chemical-biological defense contexts. Technology areas include Bio Medical and Chem Bio Defense, with biotechnology identified as the modernization priority. No CMMC level requirement applies to this opportunity.

The solicitation is structured as a multi-phase program. Phase I requires conducting a feasibility study using an existing BOND platform to demonstrate that higher Technology Readiness Levels can be achieved, with activities potentially including high-purity protein production, glycosylation advancement, lysate development, and AI/ML process analytics. Phase II seeks proposals for a ruggedized, portable biologics-on-demand system capable of producing GMP-like protein with reproducible, scalable, and high-quality output, incorporating machine learning, sensor validation, lysate optimization, and resin modification, with final demonstrations including weekly batch production with verified consistent quality. Phase III aims to deliver an FDA-ready BOND device capable of producing GMP-like proteins through manufacturing replica platforms and multiple batch runs, demonstrating capability to meet or surpass existing approved FDA protein production methods. The solicitation indicates no Technical Point of Contact is available, and no response dates, award dates, pricing terms, or specific set-asides are specified in this document.

View the file

Other files

File Type Posted
CBD_SBIR_25.4_R12.pdf PDF

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

CBD254-011: OPEN TOPIC - Expeditionary Biologics-on-Demand (BOND)

PROJECTED CMMC LEVEL REQUIREMENT:

N/A

TECHNOLOGY AREAS:

Bio Medical | Chem Bio Defense

MODERNIZATION PRIORITIES:

Biotechnology

KEYWORDS:

Protein, Manufacturing, Therapeutics, Diagnostics, Protection

ADDITIONAL INFORMATION

N/A

OBJECTIVE:

Develop a portable, high-performance BOND system for point-of-care protein production by maximizing protein purity, potency, and quality. This can be achieved through automated process control, incorporating soft sensors, machine learning, and real-time data analytics to predictively and autonomously adjust production parameters for optimal yield.

DESCRIPTION:

On-demand distributed protein production offers significant advantages, including the creation of diverse therapies, vaccines, diagnostics, and detection biologics. It also streamlines delivery, eliminates cold-chain requirements, reduces R&D costs, and enables rapid scaling for better supply-demand matching1.

Deployable, modular BOND systems can enhance supply chain resilience and broaden medical countermeasure capabilities by enabling on-site protein production in forward-deployed locations. Similar to the impact of 3D printing on manufacturing, these compact systems offer a transformative approach to producing medical treatments where they are needed. Such technologies may enable multi-nodal point-of-need manufacturing capability.

Single-platform systems have proven capable of producing a wide range of proteins due to advancements in lysate production, scaling, and automation2. However, ensuring consistent batch quality and reproducibility that meet regulatory standards remains the primary hurdle for widespread adoption of portable protein production.

Integrated analytics coupled with machine learning may offer a solution by providing unprecedented levels of batch purity and consistency.

PHASE I:

The objective of Phase I is to conduct a feasibility study using an existing BOND platform. This activity may include producing high purity proteins with consistency, advancing glycosylation approaches, developing lysate, exploring AI/ML process analytic techniques, or proposing novel anti-infectious biologics. Successful completion of Phase I should provide evidence that a higher Technology Readiness Level maybe achieved with a specified platform.

PHASE II:

This solicitation seeks proposals for a robust, portable biologics-on-demand system capable of producing GMP-like protein. Offerors must demonstrate a ruggedized BOND platform with reproducible, scalable, and high-quality throughput. Proposed solutions may involve (but are not limited to) developing ML/AI processing, sensor validation, lysate optimization, and resin modification. Final demonstration should include the production of weekly batches with verification of consistent product quality.

PHASE III DUAL USE APPLICATIONS:

PHASE III: The end goal of Phase III will be a BOND device capable of producing GMP-like proteins and ready for FDA evaluation. Such activities may include manufacturing replicate platforms and conducting multiple batch runs for product evaluation. A successful outcome of PHASE III will be to demonstrate that the BOND device is capable of meeting or surpassing existing production methods of a currently approved FDA protein.

REFERENCES:

Srai, J. S., Kumar, et al. (2016). Distributed manufacturing: scope, challenges and opportunities.

International Journal of Production Research, 54(23), 6917-6935.

1.

Borhani, S. G., Rao, G., et al. (2023). An approach to rapid distributed manufacturing of broad spectrum anti-viral griffithsin using cell-free systems to mitigate pandemics. New Biotechnology, 76, 13-22.

2.

TECHNICAL POINT OF CONTACT (TPOC):

None

File details come from the government source that posted it. Updated .